Recurring revenue loan model: Evolv's June 2027 EBITDA test

A software lender builds a recurring revenue loan model on Evolv Technologies' $75 million MidCap Financial Trust facility in Compound, from the credit agreement and eight quarters of filings: the minimum ARR schedule, the liquidity covenant, the EBITDA test added from June 30, 2027, estimated retention, a base case and a downside, runway and loan-to-value at public software multiples.

Compound Research · Updated Nov 19, 2026 · 15 min read

Short answer

A recurring revenue loan lends against a borrower's ARR rather than its EBITDA and tests it with a minimum ARR covenant. In Compound's model of Evolv Technologies' MidCap facility, the ARR test passes in both cases, but the downside misses the $10.0 million EBITDA test that starts on June 30, 2027 by $13.1 million.

Try it now
On this page (10)
  1. 1. Choosing the borrower: subscription screening, filed as hardware
  2. 2. The covenant package: three tests, and none of them converts
  3. 3. Eight quarters of ARR and estimated retention
  4. 4. Margins, operating expenses, EBITDA and cash burn
  5. 5. The base case and the downside
  6. 6. Covenant tests by quarter and the first EBITDA test
  7. 7. Loan-to-ARR, runway and loan-to-value
  8. 8. What the public filings cannot tell you
  9. 9. Our view
  10. 10. FAQ

Compound’s recurring revenue loan model for Evolv Technologies’ facility from MidCap Financial Trust shows a borrower well inside its terms today: $140.5 million of ARR against $30.0 million of funded term loan, a loan-to-recurring-revenue ratio of 0.21x, 108% net revenue retention and $81.9 million of liquidity. In the base case every covenant passes through September 30, 2028. In the downside, with 88% gross retention and slower bookings, the ARR covenant still passes, but the EBITDA test fails on its first date, June 30, 2027, and the liquidity test fails a year later.

Evolv is a subscription business, not a pure software company. It sells AI weapons-screening systems on multi-year subscriptions, and EDGAR classifies it as SIC 3577, computer peripheral equipment. Compound chose it as the only live match for every other test in the request and says so in its answer. Those results are the model’s, under its assumptions, and not a view on Evolv’s credit.

You are on the underwriting team of a direct lender or credit fund that lends to software and subscription companies against ARR. You need the covenant package as the agreement writes it, retention the company does not disclose, how long the cash lasts if bookings slow, and what the loan is worth against the equity beneath it. We asked Compound to build that model on a real borrower from public filings. It ran on November 19, 2026 and returned one Excel workbook of seven sheets and a short written answer.

What the workbook shows:

  • The facility. A $30.0 million term loan funded at closing on July 29, 2025, a $30.0 million delayed draw and a $15.0 million revolver, all maturing July 1, 2030. Pricing is Term SOFR with a 2.00% floor plus a 5.00% or 5.25% margin set by trailing EBITDA.
  • The covenants. Minimum ARR rising from $106.0 million at December 31, 2025 to $121.2 million by September 30, 2028; minimum liquidity of 50% of term loan and revolver outstandings until the litigation and regulatory matters are resolved; and a $10.0 million minimum trailing EBITDA from June 30, 2027, added alongside the ARR test.
  • The base case. ARR reaches $198.7 million by the third quarter of 2028, and covenant EBITDA at the first EBITDA test is $12.1 million.
  • The downside. ARR stays between $141.0 million and $144.4 million, net retention falls to 96%, and covenant EBITDA at the first test is negative $3.1 million.
  • The flags. Three of seven tests trip, all in the downside: runway under 12 months from the third quarter of 2027, net retention below 100%, and a failed EBITDA test at its start.

The facility terms and covenants come from the credit agreement filed as Exhibit 10.1 to a Form 8-K on SEC EDGAR, and the balance at September 30, 2026 from the 10-Q filed on November 10, 2026. ARR, customers, revenue and cash flows for each quarter come from eight earnings releases, and the 108% net retention and the expansion share of bookings from the earnings call and Investor Day transcripts. Forward rates come from Compound’s SOFR forward curve, and market capitalizations, revenue and balance sheets for Evolv and ten peers from Compound’s company financial data. Every other input is marked “Analyst assumption” with a reason.

Prompt to try

“I lend to software companies on recurring revenue and want a recurring revenue loan model built on a real borrower. From SEC EDGAR, pick one U.S. public software company with under $400 million of revenue that has a senior secured term loan from a private credit lender and reports annual recurring revenue or subscription revenue, with the credit agreement filed as an exhibit. Take the loan terms and covenants from the agreement, including any recurring revenue covenant, minimum liquidity covenant and the date it converts to an EBITDA covenant. Build quarterly history for eight quarters: recurring revenue, gross and net revenue retention as disclosed or estimated with a note, gross margin, operating expenses, EBITDA and cash burn. Project eight quarters in a base case and a downside case with higher churn and slower new bookings. Show loan-to-recurring-revenue, liquidity runway in months, the covenant tests by quarter, the quarter the EBITDA covenant starts and whether it passes, and the loan-to-value against enterprise value at public software multiples. Flag loan-to-recurring-revenue above 2.0x, runway under 12 months in the downside, net retention below 100% and a failed test at the covenant conversion. Use the stored public data wherever it has the figure, and web search only for what it lacks. Put every input on an Assumptions sheet with one column that says where it came from: a cited source, or "analyst assumption" for a figure I would set myself, with the reason for the value you chose. Every output must be a live formula that traces back to the Assumptions sheet. Add a Sources sheet listing each data source, what it gave and its date. Deliver one Excel workbook and a short summary of the result, the flags, and what I would need from the company to firm it up. Cite every sourced figure.”

Try this prompt free →

That is the request as we sent it, without its closing line, which asks that no name or email be put in the workbook.

Choosing the borrower: subscription screening, filed as hardware

Compound picked Evolv Technologies, Nasdaq: EVLV, a Waltham, Massachusetts company with $175.9 million of revenue over the four quarters to September 30, 2026, a first-lien facility from MidCap Financial Trust, quarterly ARR disclosure and the credit agreement on EDGAR. It is the closest live fit, and the fit is imperfect on the word “software.”

The workbook’s Summary describes the business as “AI-based weapons-detection screening sold mainly on multi-year subscriptions (hardware-enabled software).” The company’s EDGAR submissions file puts it under SIC 3577, computer peripheral equipment. Compound’s answer states the trade-off directly: “I picked it because it was the only live match for every other criterion.” The other candidates had dropped out: Health Catalyst had repaid its private credit loan in full, and FiscalNote was in default on its term loan.

For a lender the classification matters less than the cost base under the ARR. Evolv deploys leased screening units, so capital expenditure ran at 18.5% of revenue in the first nine months of 2026 against 21% in fiscal 2025, and GAAP gross margin sits near 50%. A pure software borrower with the same ARR would carry far less capex, which is why the cash burn and runway sections below matter as much as the ARR test.

Evolv_Recurring_Revenue_Loan_Model.xlsx
BCD
5InputUnitValue
14Agent and term loan servicertextMidCap Financial Trust
15Closing datedate7/29/2025
16Maturity date (all facilities)date7/1/2030
17Term loan tranche 1 — funded at closing$K30,000
18Term loan tranche 2 — delayed draw commitment$K30,000
19Delayed draw commitment termination datedate8/1/2027
20Revolving credit commitment$K15,000
21Revolver borrowing limit (% of ARR)%25.00%
22Term SOFR floor%2.00%
23Applicable margin — Pricing Level I (EBITDA at or above threshold)%5.00%
24Applicable margin — Pricing Level II%5.25%
25Pricing Level I EBITDA threshold (trailing 12 months)$K15,000
30Term loan amortization startdate8/1/2029
32Term SOFR in effect at September 30, 2026%3.68%
33Applicable margin in effect at September 30, 2026%5.00%
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
Facility terms from Compound's Assumptions tab, rows 14 to 33, without the fee, prepayment and amortization period rows. The source column is dropped; on the sheet each row cites the credit agreement or Note 9 of the 10-Q for the quarter ended September 30, 2026.

The all-in rate at September 30, 2026 was 8.68%: Term SOFR of 3.68% plus the 5.00% Pricing Level I margin. The revolver can be drawn only up to the lesser of its $15.0 million commitment and 25% of ARR, and the term loan is interest-only until amortization starts on August 1, 2029. The delayed draw must be taken by August 1, 2027, and the model assumes none of it is drawn.

The covenant package: three tests, and none of them converts

The agreement sets a minimum ARR schedule from December 31, 2025, a minimum liquidity of 50% of term loan and revolver outstandings, and a $10.0 million minimum trailing EBITDA from June 30, 2027. The request asked for the date the recurring revenue covenant converts to an EBITDA covenant. The document has no conversion: the EBITDA test is added on top, and the ARR test runs to maturity.

Evolv_Recurring_Revenue_Loan_Model.xlsx
BCD
5InputUnitValue
37Minimum liquidity (% of term loan + revolver outstandings) (Section 6.2)%50.00%
38Liquidity covenant still in force (1 = yes, 0 = fallen away)flag1
39Count marketable securities as unrestricted cash (1 = yes)flag1
40Minimum EBITDA, trailing 12 months (Section 6.3)$K10,000
41First minimum EBITDA test date (Section 6.3)date6/30/2027
42Cap on cash add-backs (litigation and severance) (% of EBITDA)%20.00%
43Capitalized software deduction — fixed threshold$K5,000
44Capitalized software deduction — % of EBITDA threshold%33.33%
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
The liquidity and EBITDA covenant inputs from Compound's Assumptions tab, the rows below the minimum ARR schedule, unedited except for the source column. The minimum ARR schedule sits in row 36 by quarter and is shown in the chart below.

Compound’s answer puts the reading in one line: “The ARR covenant does not convert. It stays in force, and the EBITDA test is added on top of it from Q2 2027.” The Covenants sheet labels the ARR covenant as continuing alongside to maturity and tests both from the second quarter of 2027. That matters for the downside: a borrower whose ARR holds still has to clear an EBITDA floor, so a flat-ARR, high-cost plan breaks the package even with no ARR breach.

The minimum ARR steps up each quarter, from $106.0 million at December 31, 2025 to $121.2 million at September 30, 2028. Evolv’s $140.5 million at September 30, 2026 is 27.8% above that quarter’s $110.0 million minimum.

The liquidity test is 50% of outstandings, $15.0 million on the funded $30.0 million. It falls away once the agent confirms the specified litigation and SEC and DOJ investigations are finally resolved. No such notice is disclosed, so the model keeps it in force, a switch on the Assumptions sheet the analyst can turn off. A second switch counts marketable securities as unrestricted cash, which the note says to confirm with the agent.

Covenant EBITDA follows the agreement’s compliance certificate. Cash add-backs for litigation and severance are capped at 20% of EBITDA, and capitalized software above the greater of $5.0 million and 33.33% of EBITDA is deducted. Those two clauses, not the headline $10.0 million, decide how close the first test is.

ARR against the minimum ARR covenant, base and downside

US$ thousands at each quarterly test date. Actuals through Q3'26, projections from Q4'26

100,000120,000140,000160,000180,000200,000Q2'26Q1'27Q4'27Q3'28Base case ARRDownside ARRMinimum ARR covenant

Compound's Covenants tab, rows 9, 11 and 15. Minimum ARR: credit agreement, Section 6.1.

Eight quarters of ARR and estimated retention

ARR grew from $99.4 million at December 31, 2024 to $140.5 million at September 30, 2026, with year-over-year growth slowing from 39.3% to 19.9%. The company disclosed net revenue retention only once, 108% at September 30, 2026. Every other retention figure is Compound’s estimate, and gross retention is never disclosed.

Evolv_Recurring_Revenue_Loan_Model.xlsx
L22fx=L21-L20/Assumptions!L52
BEFGHIJKL
5QuarterQ4'24AQ1'25AQ2'25AQ3'25AQ4'25AQ1'26AQ2'26AQ3'26A
9ARR, period end ($K)99,351105,990110,516117,200120,467127,300132,680140,510
11ARR growth, year over year39.3%33.8%27.0%25.1%21.3%20.1%20.1%19.9%
12New customers added6054636264487051
13Recurring revenue23,67825,75326,37928,68429,54731,17632,08732,548
15Subscription revenue17,26319,23720,20022,68521,71723,14824,78524,488
18Net revenue retention, as disclosedn.d.n.d.n.d.n.d.n.d.n.d.n.d.108.0%
19New-logo ARR added, trailing 4 quarters (estimate)14,94015,00013,74014,34014,58014,22014,64013,980
20Expansion ARR, trailing 4 quarters (estimate)14,94015,00013,74014,34014,58014,22014,64013,980
21Net revenue retention, estimated118.4%114.9%111.2%109.8%106.6%106.7%106.8%108.0%
22Gross revenue retention, estimated97.4%96.0%95.4%94.5%91.9%93.3%93.6%96.0%
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
Recurring revenue and retention from Compound's History tab, rows 9 to 22, without the quarter-over-quarter growth, the run-rate ratio and the flag rows. The formula bar shows gross retention as estimated net retention less estimated expansion over ARR a year earlier.

The estimate starts from new customers, which the company reports each quarter. Compound multiplies them by an initial $60 thousand of ARR per new customer to get new-logo ARR, then sets expansion ARR equal to it, because the Investor Day 2026 transcript says about half of new unit bookings come from existing customers. Net retention is ARR today less the year’s new-logo ARR, over ARR a year earlier. The $60 thousand is calibrated so that the estimate lands on the disclosed 108% at September 30, 2026, and it does, at 108.0%.

On that method net retention fell from 118.4% at December 31, 2024 to 106.6% a year later and has held near 107% since. Estimated gross retention bottomed at 91.9% in the fourth quarter of 2025 and recovered to 96.0%. Both lines rest on one calibration point and one disclosed split, so a lender would treat them as a range until the company provides an ARR bridge.

Recurring revenue, $32.5 million in the third quarter of 2026, is wider than subscription revenue of $24.5 million. Compound’s answer asks for the split of ARR between pure subscription and purchase subscription for that reason: the ARR the covenant counts includes contracts where the customer bought the hardware.

Margins, operating expenses, EBITDA and cash burn

GAAP gross margin fell from 57.5% to 49.7% over the eight quarters, and Adjusted EBITDA rose to $4.7 million in the third quarter of 2026, a 10.0% margin. Free cash flow has been positive in three of the last four quarters, so the latest liquidity runway reads cash generative.

Evolv_Recurring_Revenue_Loan_Model.xlsx
L58fx=IF(L46>0,L56/(L46/Assumptions!$D$144),Assumptions!$D$145)
BEFGHIJKL
5QuarterQ4'24AQ1'25AQ2'25AQ3'25AQ4'25AQ1'26AQ2'26AQ3'26A
26Total revenue ($K)29,10032,00732,54442,85038,50446,32843,75347,345
30Gross margin (GAAP)57.5%59.8%49.8%49.7%48.4%50.9%50.2%49.7%
33Cash gross margin (proxy)76.2%77.1%67.6%65.0%65.2%65.6%66.5%65.5%
35Adjusted operating expenses (company non-GAAP)23,10123,18121,64024,81123,83226,89824,99826,546
38Adjusted EBITDA ($K)3712,0642,1025,1311,8173,9444,4314,749
39Adjusted EBITDA margin1.3%6.4%6.5%12.0%4.7%8.5%10.1%10.0%
42Cash from operations (quarter)3,204(2,539)2,1133,52415,571(3,179)11,90217,962
43Purchases of property and equipment (quarter)(6,746)(12,730)(2,569)(13,810)(2,258)(3,742)(8,395)(13,274)
44Capitalized internal-use software (quarter)(1,352)(1,556)(1,556)(1,199)(1,316)(1,223)(1,417)(1,441)
45Free cash flow ($K)(4,894)(16,825)(2,012)(11,485)11,997(8,144)2,0903,247
56Liquidity, covenant definition ($K)51,94235,02036,94271,22784,03576,07377,63281,861
58Liquidity runway (months; FCF+ = cash generative)31.86.255.118.6FCF+28.0FCF+FCF+
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
Selected rows of Compound's History tab, rows 26 to 58: revenue, margins, EBITDA, free cash flow, liquidity and runway. Growth, GAAP operating expense, add-back, balance and leverage rows are dropped. Runway shows "FCF+" in quarters with positive free cash flow; the formula bar shows the calculation.

Compound uses a cash gross margin, GAAP gross profit plus depreciation and amortization, because the leased units sit in cost of revenue. On that basis margin has held near 65% since the second quarter of 2025. Adjusted operating expenses, the company’s non-GAAP figure, ran between $21.6 million and $26.9 million a quarter.

Free cash flow is the company’s definition: operating cash flow less capex and capitalized software. Capex swings with deployments, from $2.3 million in the fourth quarter of 2025 to $13.3 million in the third quarter of 2026. Cash burn peaked at $16.8 million in the first quarter of 2025, when runway fell to 6.2 months on the liquidity of the time. That quarter predates the MidCap facility. Since closing, liquidity has stayed between $71.2 million and $84.0 million.

The base case and the downside

The base case holds 95% gross retention and 13% expansion, so net retention stays at 108%, and grows new customers from 62 a quarter. The downside cuts gross retention to 88%, expansion to 8% and new customers to 40 a quarter at $55 thousand each, with no cost response. Downside ARR stops growing, and free cash flow turns to a burn of about $9 million to $12 million a quarter.

The base case adds an 11% step-up in adjusted operating expenses in the fourth quarter of 2026, for the sales, R&D and controls investment flagged on the third quarter call, then 2% a quarter. That lands fiscal 2026 Adjusted EBITDA at $16.5 million, inside the $15.5 million to $16.5 million guidance, and fiscal 2026 ending ARR at $147.1 million, $1.9 million under the $148.0 million low end of guidance. Base-case free cash flow is negative from the fourth quarter of 2026 to the fourth quarter of 2027, at $3.9 million in the first of those quarters, and the lowest base-case runway is 60.0 months.

Evolv_Recurring_Revenue_Loan_Model.xlsx
I75fx=-I74*(1-Assumptions!Q101^(1/Assumptions!$D$143))
BIJKLMNOP
5QuarterQ4'26EQ1'27EQ2'27EQ3'27EQ4'27EQ1'28EQ2'28EQ3'28E
74Beginning ARR140,510141,020141,524142,022142,514143,000143,480143,955
75(-) Churn(4,419)(4,436)(4,451)(4,467)(4,483)(4,498)(4,513)(4,528)
76(+) Expansion2,7302,7402,7492,7592,7692,7782,7872,797
77(+) New-logo ARR2,2002,2002,2002,2002,2002,2002,2002,200
78Ending ARR ($K)141,020141,524142,022142,514143,000143,480143,955144,424
80Net revenue retention (annualized)96.0%96.0%96.0%96.0%96.0%96.0%96.0%96.0%
86Total revenue ($K)43,98744,11244,23444,35644,47544,59444,71144,826
91Adjusted EBITDA ($K)1,249762263(249)(775)(1,315)(1,869)(2,436)
126Free cash flow ($K)(8,933)(9,533)(10,148)(10,773)(9,911)(10,552)(11,212)(11,854)
129Cash and marketable securities, closing ($K)57,92848,39638,24827,47517,5647,012(4,199)(16,053)
131Liquidity, covenant definition ($K)72,92863,39653,24842,47532,56422,01210,801(1,053)
132Liquidity runway (months; FCF+ = cash generative)24.520.015.711.89.96.32.90.0
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
Selected rows of the downside block on Compound's Projections tab, for the eight projected quarters. Gross retention, margin, covenant EBITDA, debt and cash flow detail rows are dropped. The formula bar shows quarterly churn converted from the 88% annual gross retention.

The downside ARR build shows why the ARR test survives. Churn of about $4.4 million a quarter is offset by $2.7 million of expansion and $2.2 million of new-logo ARR, so ARR still edges up by about $0.5 million a quarter (our arithmetic). The covenant schedule rises faster, and headroom narrows from 27.8% to 19.1%, but stays positive.

The cost side breaks first. The downside keeps the base-case spend path, “to isolate the revenue stress,” while non-recurring revenue drops to $9.5 million a quarter and legal costs run at $2.0 million a quarter through the third quarter of 2027. Adjusted EBITDA turns negative in the third quarter of 2027, and cash and marketable securities fall below zero in the second quarter of 2028. The model does not draw the revolver or the delayed draw to cover the gap, so covenant liquidity, which counts the $15.0 million of undrawn revolver, is negative $1.1 million by the third quarter of 2028.

Covenant tests by quarter and the first EBITDA test

In the base case every test passes in every quarter, and covenant EBITDA at June 30, 2027 is $12.1 million against the $10.0 million minimum. In the downside the ARR test passes throughout, the EBITDA test fails from its first date at negative $3.1 million, and the liquidity test fails from the second quarter of 2028.

Evolv_Recurring_Revenue_Loan_Model.xlsx
BEFGHIJKLMNOP
5QuarterQ4'25AQ1'26AQ2'26AQ3'26AQ4'26EQ1'27EQ2'27EQ3'27EQ4'27EQ1'28EQ2'28EQ3'28E
9Required minimum ARR ($K)106,000107,325108,650109,975111,300112,691114,083115,474116,865118,325119,787121,247
15ARR120,467127,300132,680140,510141,020141,524142,022142,514143,000143,480143,955144,424
16Headroom over minimum13.6%18.6%22.1%27.8%26.7%25.6%24.5%23.4%22.4%21.3%20.2%19.1%
28Liquidity (unrestricted cash + revolver availability)84,03576,07377,63281,86172,92863,39653,24842,47532,56422,01210,801(1,053)
30ResultPASSPASSPASSPASSPASSPASSPASSPASSPASSPASSFAILFAIL
33Test in effect (1 = yes)000000111111
40Covenant EBITDA, trailing 12 months (proxy)5,43111,68015,27514,1759,1342,990(3,142)(6,371)(7,299)(8,292)(9,350)(10,474)
42ResultNot testedNot testedNot testedNot testedNot testedNot testedFAILFAILFAILFAILFAILFAIL
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
Selected downside rows of Compound's Covenants tab, rows 9 to 42: the ARR test, the liquidity test and the EBITDA test. The base-case block, the ARR result row (a pass in every quarter), required liquidity and the cushion rows are dropped. Q4'25 to Q3'26 are proxy calculations from reported figures.

The base case passes the EBITDA test with a cushion of $2.1 million, 21.4% over the minimum. The cushion is thinner than trailing Adjusted EBITDA of $17.3 million suggests, and the build shows why.

Evolv_Recurring_Revenue_Loan_Model.xlsx
K35fx=-MAX(0,K34-Assumptions!$D$42*K33)
BHIJKLM
5QuarterQ3'26AQ4'26EQ1'27EQ2'27EQ3'27EQ4'27E
33Adjusted EBITDA, trailing 4 quarters14,94116,48116,69917,26118,36421,747
34Legal and regulatory add-backs, trailing 4 quarters3,3576,5827,6817,7784,0003,000
35(-) Cash add-backs above the 20% cap(369)(3,286)(4,341)(4,326)(327)-
36Capitalized software, trailing 4 quarters5,3975,5315,7585,7915,8005,800
37(-) Capitalized software above threshold(397)(531)(758)(791)--
38Covenant EBITDA, trailing 12 months ($K)14,17512,66511,60012,14418,03721,747
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
The base-case covenant EBITDA build from Compound's Projections tab, rows 33 to 38, unedited, for the Q3'26 to Q4'27 columns. The formula bar shows the 20% cap on cash add-backs at the first test.

At June 30, 2027 the trailing four quarters still include the $4.8 million of legal and regulatory costs added back in the third quarter of 2026. Legal add-backs total $7.8 million against a cap of 20% of EBITDA, so $4.3 million is excluded, and $0.8 million of capitalized software above the threshold comes off too. A quarter later the third quarter of 2026 rolls out and covenant EBITDA jumps to $18.0 million. The first test date is the tightest one in the base case, and it is tight because of when the litigation costs fell.

The same build moves the price. Covenant EBITDA at September 30, 2026 is $14.2 million, below the $15.0 million Pricing Level I threshold, so the model steps the margin to 5.25% from the fourth quarter of 2026 and back to 5.00% in the fourth quarter of 2027. The all-in rate peaks at 9.94% in the third quarter of 2027 on the forward curve. Compound checks the proxy against the facility: its $15.3 million at June 30, 2026 is consistent with the 5.00% margin the 10-Q reports at September 30, 2026.

Covenant EBITDA at the first test, June 30, 2027, against the minimum

Trailing 12 months, US$ thousands. The June 30, 2026 figure is Compound's proxy from reported results

Proxy at June 30, 202615,275Base case12,144Minimum EBITDA covenant10,000Downside case-3,142

Compound's Covenants tab, rows 34, 36 and 40. Minimum EBITDA: credit agreement, Section 6.3.

The downside fails for two reasons that compound. Adjusted EBITDA falls to $7.0 million on a trailing basis by June 30, 2027 because revenue is flat and spend is not. Then the higher downside legal costs push $10.8 million of add-backs against the 20% cap, and $9.4 million of them are excluded. The shortfall is $13.1 million. The verdict follows directly from the assumption of no cost response; a borrower that cut spending as bookings slowed would land closer to the line.

Loan-to-ARR, runway and loan-to-value

Funded debt is 0.21x ARR today and peaks at 0.26x, at the facility’s first quarter, against the 2.0x flag. Fully drawn, the $75.0 million facility is 0.53x ARR. At the peer median of 3.3x LTM revenue, the term loan is 5.2% of enterprise value, or 12.9% fully drawn.

Evolv_Recurring_Revenue_Loan_Model.xlsx
F37fx=F36/F35
BEFGH
33Low (25th)MedianHigh (75th)Evolv market
34EV / LTM revenue multiple2.2x3.3x4.4x3.8x
35Implied enterprise value ($K)384,580582,122781,443672,356
36Funded debt ($K)30,00030,00030,00030,000
37Loan-to-value, funded debt7.8%5.2%3.8%4.5%
38Total facility commitments, fully drawn ($K)75,00075,00075,00075,000
39Loan-to-value, fully drawn19.5%12.9%9.6%11.2%
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
Current loan-to-value from Compound's Valuation tab, rows 33 to 39, unedited. Peer multiples are enterprise value over LTM revenue for ten security, safety and hardware-enabled subscription companies.

The peer set runs from SoundThinking at 1.1x LTM revenue to Samsara at 11.7x, with Axon Enterprise, Alarm.com, Arlo Technologies, Napco Security, Mitek Systems, OneSpan, Rapid7 and Digi International between. Evolv’s own market capitalization of $709.2 million on November 19, 2026 gives an enterprise value of $672.4 million, 3.8x LTM revenue and 4.8x ARR. At the third quarter of 2028 the downside, valued at the 25th percentile multiple of 2.2x, puts the term loan at 7.7% of enterprise value and the full facility at 19.2%.

Loan-to-value is not where the downside bites. Runway is. The downside’s runway, liquidity over monthly burn, falls from 24.5 months in the fourth quarter of 2026 to 11.8 months in the third quarter of 2027, which trips the 12-month flag, and reaches zero a year later.

Evolv_Recurring_Revenue_Loan_Model.xlsx
BEFG
42TestThresholdMeasuredStatus
43Loan-to-recurring-revenue above 2.0x2.00x0.26xOK
44Downside liquidity runway under 12 months12.00.0FLAG
45 First downside quarter under 12 monthsQ3'27E
46Net revenue retention below 100% — latest actual100.0%108.0%OK
47Net revenue retention below 100% — base case100.0%108.0%OK
48Net revenue retention below 100% — downside case100.0%96.0%FLAG
49Failed test at EBITDA covenant start — base case10,00012,144OK
50Failed test at EBITDA covenant start — downside case10,000(3,142)FLAG
51Flags raised3
SummaryAssumptionsHistoryProjectionsCovenantsValuationSources
The flags from Compound's Summary tab, rows 42 to 51, without the column that says where each test is measured.

Covenant liquidity by quarter, base and downside, against the minimum

US$ thousands: unrestricted cash and marketable securities plus revolver availability

-20,000020,00040,00060,00080,000100,000Q3'26Q1'27Q3'27Q1'28Q3'28Base caseDownsideMinimum liquidity

Compound's Covenants tab, rows 22, 23 and 28. Minimum liquidity: credit agreement, Section 6.2.

What the public filings cannot tell you

The credit agreement and the earnings releases give the terms, the ARR and the cash. Covenant EBITDA, retention and the composition of ARR come from the borrower. Compound’s answer lists six requests, and each replaces a specific estimate in the model.

  • Monthly ARR and liquidity certificates and the quarterly compliance certificates, including the agreement-basis EBITDA build and the add-backs counted against the 20% cap. These replace the covenant EBITDA proxy, the model’s largest estimate.
  • A quarterly ARR bridge (new, expansion, downgrade, churn), gross and net retention by cohort, and the renewal schedule for four-year contracts coming due. These replace the $60 thousand calibration and the estimated 96% gross retention, and test whether the downside’s 88% is the right stress for first-generation renewals.
  • ARR split between pure subscription and purchase subscription, plus unit counts, ARPU and Gen1-to-Gen2 upgrade economics.
  • The 2027 budget and monthly cash forecast: hiring, leased-unit capex, deferred revenue, and any planned delayed-draw or revolver use before August 1, 2027.
  • Status, cost and insurance cover for the litigation settlement and the SEC and DOJ matters, and when the liquidity covenant is expected to fall away. These set the legal cost path that decides the first EBITDA test.
  • The fee letter terms, and any amendments, waivers or consents since closing.

Our view

The model reads the covenant package correctly where the request did not, and its most useful output is the first EBITDA test date. We would keep the structure, treat the June 30, 2027 test as the event to underwrite, and spend diligence on the compliance certificate and the legal cost run-off.

Under the model’s assumptions the loan is small against the business. Funded debt is 0.21x ARR, the term loan is 5.2% of enterprise value at the peer median, and the ARR covenant still has 19.1% of headroom at the end of the downside. A lender sizing on ARR alone would see a conservative loan. These are the model’s results, not a view on Evolv’s credit.

The other side is that the package does not rest on ARR alone. The EBITDA floor added from June 30, 2027 and the 20% cap on add-backs make the first test sensitive to the timing of litigation costs, and the downside fails it with ARR intact. The base-case cushion of $2.1 million depends on legal costs falling to $1.0 million a quarter. The downside also assumes no cost response and no revolver draw, which makes it a stress on management behavior as much as on churn.

Three findings would change our view: compliance certificates showing covenant EBITDA well below the $14.2 million proxy, cohort data putting gross retention near the downside’s 88%, and a litigation outcome that keeps legal costs above the base case into 2027. From here the work is a credit agreement analysis of the full EBITDA definition and a covenant compliance calculation on the borrower’s own certificate.

Evolv recurring revenue loan model (Excel)Compound’s workbook from this run: a Summary with the flags, an Assumptions sheet with a source or reason beside every input, eight quarters of History, base and downside Projections, the Covenant tests by quarter, the Valuation against ten peers, and Sources.Download · Free

FAQ

How does a minimum ARR covenant work in a recurring revenue loan?

The agreement sets a floor on ARR at each quarterly test date, usually stepping up over the life of the loan. Evolv’s starts at $106.0 million at December 31, 2025 and rises to $121.2 million by September 30, 2028. The model tests reported ARR against it each quarter, with 27.8% headroom at September 30, 2026.

Does a recurring revenue covenant always convert to an EBITDA covenant?

No. Many agreements flip from an ARR test to a leverage or EBITDA test at a set date, but Evolv’s adds a $10.0 million minimum EBITDA test from June 30, 2027 and keeps the ARR test to maturity. Read the covenant article before building the model, because a converting and an additive package fail in different cases.

How do you estimate net revenue retention when the company does not disclose it?

Back it out from ARR and new-logo bookings: ARR today less the year’s new-logo ARR, over ARR a year earlier. Compound sets ARR per new customer so the estimate matches the one disclosed figure, 108% at September 30, 2026, and uses the company’s statement that about half of bookings are expansion to estimate gross retention.

Why is covenant EBITDA lower than Adjusted EBITDA?

The credit agreement caps cash add-backs for litigation and severance at 20% of EBITDA and deducts capitalized software above a threshold. With heavy legal costs in the trailing four quarters, the cap removes $4.3 million in the base case at June 30, 2027, taking $17.3 million of Adjusted EBITDA to $12.1 million of covenant EBITDA.

How is liquidity runway calculated for an ARR borrower?

Covenant liquidity, unrestricted cash plus revolver availability, divided by monthly cash burn, where burn is the free cash flow deficit. Quarters with positive free cash flow read cash generative. In Evolv’s downside, runway falls below 12 months in the third quarter of 2027.

CoatueCentri ConsultingAvra783 Capital PartnersOctahedron CapitalArix ResearchCoatueCentri ConsultingAvra783 Capital PartnersOctahedron CapitalArix ResearchCoatueCentri ConsultingAvra783 Capital PartnersOctahedron CapitalArix Research

See this workflow on your own deal

Try it now